McCurdy, Victoria J.
Johnson, Aime K.
Gray-Edwards, Heather L.
Randle, Ashley N.
Bradbury, Allison M.
Morrison, Nancy E.
Hwang, Misako
Baker, Henry J.
Cox, Nancy R.
Sena-Esteves, Miguel
Martin, Douglas R. http://orcid.org/0000-0002-3444-8407
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01NS064096, U01NS064096, U01NS064096, U01NS064096, U01NS064096, U01NS064096, U01NS064096, U01NS064096)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 19 December 2019
Revised: 10 July 2020
Accepted: 19 August 2020
First Online: 3 September 2020
Compliance with ethical standards
:
: The authors are beneficiaries of a licensing agreement with Axovant Gene Therapies (New York City) based partly on this technology. MS-E and DRM are shareholders in Lysogene (Neuilly-sur-Seine, France).